The treatment of melanoma, the most aggressive form of skin cancer, is being revolutionized by the development of personalized targeted therapy approaches. Mutant-selective BRAF inhibitors and MEK inhibitors have demonstrated impressive clinical results in molecularly selected patients. However, emerging understanding of the molecular heterogeneity of this disease and the identification of multiple mechanisms of resistance to targeted therapies strongly support the rationale for combinatorial approaches. In this review, we will discuss the preclinical and clinical studies that are testing leading hypotheses and emerging combinatorial strategies for the future.
INTRODUCTION
Melanoma is the most aggressive form of skin cancer. While melanoma represents o10% of all skin cancers that are diagnosed, it is responsible for 475% of skin cancer-related deaths. As the incidence of melanoma increased more than 600% between 1950 and 2000, it is likely to become an increasingly important public health problem in the future. 1 The clinical management of melanoma is evolving rapidly owing to the identification of oncogenic drivers in most patients. The sentinel event in this field was the discovery of hotspot mutations in BRAF, a key serine-threonine kinase in the RAS-RAF-MEK-ERK signaling pathway, in 2001. 2 Activating BRAF mutations are detected in B50% of cutaneous melanomas that lack evidence of chronic sun damage, which are the most common type. BRAF mutations are also present in the other clinical subtypes of melanoma, but at a much lower frequency (for example, B5% of mucosal melanomas). 3 Activating mutations in NRAS are the second most common genetic aberration in melanoma. NRAS mutations are detected in B20% of cutaneous melanomas, and are almost always mutually exclusive with activating BRAF mutations in treatment-naïve patients. Recently, two independent reports of the results of whole-exome sequencing of cohorts of 4100 cutaneous melanoma have been reported, and have identified a variety of additional somatic alterations, including mutations that occur specifically in tumors that have wild-type BRAF and NRAS genes. 4, 5 Further, several oncogenic mutations have been identified in other melanoma subtypes (KIT, GNaQ, GNa11 and BAP1).
6-10
The identification of frequent oncogenic events has rapidly translated into clinical impact in melanoma. Several reports support that these mutations have prognostic significance in various clinical settings, which has implications for risk stratification for patient management and clinical trial design. [11] [12] [13] More importantly, treatment with vemurafenib, a selective inhibitor of V600-mutant BRAF, improved clinical response rates, progressionfree survival and overall survival in metastatic melanoma patients with activating BRAF mutations compared with chemotherapy in the BRIM3 phase III clinical trial, leading to its regulatory approval.
14 Similar clinical benefit has also been reported for dabrafenib, a structurally unrelated selective V600-mutant BRAF inhibitor. 15 However, the clinical benefit of single-agent BRAF inhibitor therapies have been critically limited by the rapid development of resistance.
Multiple lines of both clinical and preclinical research are now providing strong evidence to support the development of combinatorial approaches as a therapeutic strategy in melanoma. This review will highlight recent advances in this area, and discuss emerging strategies and challenges to improve outcomes in this highly aggressive disease.
BRAF-MUTANT MELANOMA
The marked clinical benefit achieved by both vemurafenib and dabrafenib in metastatic melanoma patients with activating BRAF mutations serves as a powerful example of the tremendous potential for personalized, targeted therapy approaches for cancer. RECIST criteria response rates for both of these agents were B50% in phase III trials, and o10% of patients experienced disease progression as their best response. 14, 15 However, the initial enthusiasm for these agents has been dampened by the development of acquired resistance in nearly all responding patients. The median duration of the clinical responses reported with these agents in phase III clinical trials has been only 5-6 months, and the overwhelming majority of patients have relapsed in o1 year. Molecular analysis of clinical and preclinical research has rapidly identified multiple mechanisms of resistance. In turn, these findings have suggested candidate combinatorial approaches that are now entering the clinical arena (Table 1) .
Dual inhibition of the MAPK pathway
The clinical development of the selective BRAF inhibitors has reinforced the critical significance of the activation of the MAPK signaling pathway in the pathogenesis of melanoma. In the phase I clinical trial of vemurafenib, a nearly linear relationship was identified between the degree of pathway inhibition achieved, as measured by reduction in phosphorylated ERK (P-ERK) in the 16 Clinical responders also demonstrated significantly (Po0.01) greater inhibition of P-ERK than non-responders in the phase II study of vemurafenib. 17 Consistent with these results as an early predictive pharmacodynamic index, increased P-ERK signaling has been a common feature of many clinical specimens obtained from patients at the time of disease progression on selective BRAF inhibitors. 17, 18 Reactivation of ERK has also been observed in multiple cell lines selected for resistance in vitro by long-term exposure to selective BRAF inhibitors. [19] [20] [21] [22] Analysis of progressing clinical specimens and resistant cell lines has identified a variety of molecular mechanisms that re-activate signaling by MEK and ERK (Figure 1a) . Interestingly, to date no secondary mutations in the BRAF gene itself have been identified in patients or resistant cell lines, although it has been shown that certain gatekeeper mutations could cause resistance to the selective BRAF inhibitors. 23 However, two other alterations of BRAF have been observed: gene copy number gain and alternative splicing. Copy number gain of the mutant allele of BRAF was identified in 4 of 20 patients analyzed by whole-exome sequencing, although the rate of true gene amplification (45 copies) was low. 24 In vitro testing of cell lines with BRAFi resistance owing to increased copy number demonstrated that growth inhibition could be achieved by treatment with higher doses of BRAF inhibitors. In contrast, alternative splicing of the mutant BRAF, which was detected in several cell lines selected for resistance to selective BRAF inhibitors and in 6 of 19 patients at the time of disease progression, results in a smaller protein that efficiently forms dimers that cannot be inhibited by the selective BRAF inhibitors. 21 Cell lines expressing the splice variant demonstrate persistent activation of, and dependence upon, MEK and ERK signaling, as inhibition of these downstream components of the pathway inhibits cell growth and survival. Other resistance mechanisms that are characterized by continued dependence upon MEK and ERK include mutations of NRAS or MEK; overexpression of CRAF or COT; and utilization of other RAF isoforms. 25 Despite the evidence that re-activation of MEK is a frequent event at the time of disease progression on selective BRAF inhibitors, the clinical activity of MEK inhibitors in these patients has been limited. Trametinib is a MEK inhibitor that produces significant improvements in clinical response rate, progressionfree survival and overall survival compared with chemotherapy in metastatic melanoma patients with activating BRAF mutations not previously treated with selective BRAF inhibitors. 26 In contrast, no clinical responses were seen in patients treated with trametinib who had previously progressed on a selective BRAF inhibitor. 27 Slightly better results were observed with combined treatment with trametinib and dabrafenib. In a cohort of 26 patients who had previously progressed on a selective BRAF inhibitor, 5 patients (19%) achieved a partial response and several patients achieved minor responses. 28 No information is currently available about the resistance mechanisms to selective BRAF inhibitors among the patients who responded to the combination, nor the effects of the combination on P-ERK. The safety and efficacy of this same combination in patients not previously exposed to selective BRAF inhibitors have also been reported recently. Phase I testing demonstrated that the full doses of dabrafenib and trametinib were well tolerated, with an apparent decrease in the prevalence and severity of cutaneous toxicities that are incurred with singleagent BRAF inhibitors. 29 This effect is likely due to the blockade of the paradoxical activation of MEK and ERK signaling that is observed in cells with wild-type BRAF and activated RAS, and is consistent with preclinical experiments with the combination. 30 A randomized phase II trial in which patients were treated with dabrafenib with or without trametinib demonstrated that the combination produced significant improvements in clinical response rate (76% vs 54%), progression-free survival (median Table 1 . . 31 Longer follow-up is needed to fully evaluate the durability of the responses with this regimen, and to understand the molecular features and causes of resistance. Combinatorial approaches targeting other components of the MAPK pathway, including ERK, are also being investigated.
The PI3K-AKT pathway While re-activation of MEK and ERK in melanomas is common at the time of resistance to selective BRAF inhibitors, it is not universal. Both clinical specimens and cell lines with secondary resistance to the BRAF inhibitors have been identified with continued inhibition of the MAPK pathway. Overexpression and hyperactivation of receptor tyrosine kinases (RTKs) at the time of progression has been identified in a number of these samples ( Figure 1b ). The RTKs with the strongest evidence and supporting functional studies are PDGFbR and IGF1R, although increased expression of other receptors has been noted as well. 19, 20 The increased expression of the RTKs at disease progression appears to be due to epigenetic mechanisms, as there has been no evidence of either gene mutation or amplification in the resistant samples. Increased expression of IGF1R has also been associated with de novo resistance to cell killing by both BRAF and MEK inhibitors in preclinical models. 32, 33 Evidence from multiple laboratories supports that the activation of the RTKs induces compensatory activation of the PI3K-AKT pathway in the setting of BRAF or MEK inhibition. [32] [33] [34] A recent study has also demonstrated that compensatory activation of RTKs and resistance to BRAF inhibitors can be induced by increased production of growth factors by nontransformed cells in the tumor microenvironment. 35 Stromal cell lines that secreted hepatocyte growth factor (HGF) were able to induce resistance to selective BRAF inhibitors when they were grown in co-culture with BRAF-mutant melanoma cell lines. The investigators demonstrated that HGF did not rescue MAPK pathway signaling, but instead it induced marked activation of AKT. The HGF-induced resistance could be overcome by combining the BRAF inhibitors with HGF neutralizing antibodies, MET (the RTK for HGF) inhibitors or AKT inhibitors. Critically, analysis of tumor biopsies from patients treated with BRAF inhibitors demonstrated that stromal expression of HGF correlated with inferior treatment outcomes, supporting the clinical relevance of these findings.
The PI3K-AKT pathway can also be constitutively activated by loss of function of the tumor suppressor PTEN. Loss of PTEN has been reported in 20-30% of melanomas. 36 While PTEN loss is mutually exclusive with the presence of an activating NRAS mutation, it is frequently detected in melanomas with an activating BRAF mutation. 37, 38 Preclinical studies by several labs have shown that BRAF-mutant, PTEN-null human melanoma cell lines undergo growth inhibition following treatment with BRAF or MEK inhibitors, but they generally do not undergo cell death. 32, 39, 40 Clinically, genetic abnormalities (mutations or deletions) in the PTEN gene were associated with shorter progression-free survival in patients treated in the dabrafenib phase I trial, and the expression of PTEN protein was lower in nonresponders compared with responders in the phase II trial of vemurafenib. 17, 41 The acquisition of PTEN loss at the time of disease progression on a selective BRAF inhibitor was also identified in one of five patients in one study. 20 Studies in both the RTK-overexpressing and PTEN-null BRAFmutant human melanoma cell lines support that combined treatment with BRAF (or MEK) inhibitors with PI3K-AKT pathway inhibitors can induce synergistic cell killing and overcome resistance. While these preclinical results are promising, the clinical development of inhibitors against the PI3K-AKT pathway has been challenging. Although there are many agents available for clinical testing, there remains limited information about the degree of target inhibition achieved at clinically tolerated doses. Further, there are multiple feedback loops within the PI3K-AKT pathway that can be altered by inhibition of individual targets, resulting in compensatory pro-survival signaling within this pathway, and in others. [42] [43] [44] Thus, effective targeting of the pathway will likely require combinatorial approaches that block compensatory signaling. Further, personalized targeting of this pathway may be optimized by identifying the specific kinases, and potentially the specific kinase isoforms, that are critical to the prosurvival effects of different aberrations that activate the pathway (that is, different RTKs, PTEN).
Immunotherapy
In addition to targeted therapy, immunotherapies have been extensively investigated in melanoma as a therapeutic strategy. Two immunotherapies, high-dose interleukin-2 and ipilimumab, are approved by the FDA for the treatment of unresectable or Combinatorial targeted therapy for melanoma LN Kwong and MA Davies metastatic melanoma. Both of these agents are associated with relatively low clinical response rates (10-15%). However, the majority of complete responders (B5%) to high-dose interleukin-2 achieve long-term (45-10 year) remissions, and ipilimumab achieves 3-4 year disease control rates of 20-30%. [45] [46] [47] [48] As the key clinical limitation of the selective BRAF inhibitors is the short duration of clinical responses, there is hope that combining these agents with immunotherapies may achieve high rates of durable disease control. This hope for achieving synergistic effects by combining these two treatment modalities is now also supported by analysis of the immunologic effects of the BRAF inhibitors. Treatment of BRAF-mutant human melanoma cell lines with selective BRAF inhibitors induced increased expression of melanocyte differentiation antigens on the surface of the tumor cells, and improved recognition by T cells. 49 While MEK inhibitors also induced the expression of melanocyte differentiation antigens, they impaired the function of T cells, a deleterious effect that was not seen with the selective BRAF inhibitors. Analysis of tumor biopsies from 15 BRAF-mutant patients treated with selective BRAF inhibitors for B1 week demonstrated increased intra-tumoral and peri-tumoral T cells in the majority, supporting a positive interaction in vivo. 50 A separate study of peripheral blood from patients receiving dabrafenib also demonstrated a lack of inhibition of T-cell viability or function, consistent with the preclinical studies. 51 The results overall support the rationale for clinical trials testing the clinical benefit of combining BRAF inhibitors and immunotherapies and the evaluation of immune effects of other targeted therapy regimens. Further investigations, however, will be needed to determine optimal combinations, treatment schedules and patients for this combinatorial strategy.
NRAS-MUTANT MELANOMA
In contrast to the rapid and successful development of targeted therapies against mutant BRAF, targeting melanomas with activating NRAS mutations remains an important unmet need. The clinical significance of this problem is reinforced by the association of NRAS mutations with high-risk tumor features and shorter survival in both early-and late-stage melanoma patients. 11, 13, 52 Molecularly, gain of chromosome 7 is more significantly associated with BRAF than NRAS melanoma, though it is worth noting that the BRAF gene is on chromosome 7. 24 In mouse models, transgenic NRAS Q61K , but not BRAF V600E , expression coupled with loss of CDKN2A is sufficient to induce melanomagenesis with high penetrance. [53] [54] [55] The lack of direct RAS inhibitors has necessitated approaches that target downstream effectors. BRAF inhibitors are of doubtful benefit in these patients, as mutant NRAS signals primarily through CRAF and not BRAF. 56 Indeed, treatment of NRAS melanomas with mutant-specific BRAF inhibitors elicits paradoxical activation of MAPK signaling via increased dimerization of BRAF and CRAF. [57] [58] [59] Thus, distinct combinatorial approaches will likely be needed for NRAS-and BRAF-mutant melanomas.
Targeting the MAPK pathway The clinical success of the MEK inhibitor trametinib for patients with activating BRAF mutations also holds hope for NRAS patients, as the centrality of MEK-ERK signaling is well established for both oncogenes. 54, 60 However, single-agent treatment with MEK inhibitors have demonstrated limited clinical efficacy in NRASmutant melanoma patients. Trametinib failed to achieve any objective clinical responses among nine NRAS-mutant melanoma patients, and only three even achieved stable disease. 61 The MEK inhibitor selumetinib also produced no objective responses in nine NRAS patients. 62 More promisingly, MEK162 achieved clinical responses in more than a fifth of 28 NRAS-mutant metastatic melanoma patients, and another third had stable disease. 63 However, the duration of the MEK162 responses was quite short. Whether or not the higher response rate represents more favorable properties of MEK162 compared with trametinib or selumetinib will require larger cohorts and deeper characterizations of clinical activity. In spite of their drawbacks as single agents, MEK inhibitors, and/ or possibly emerging ERK inhibitors, will likely be cornerstones for combinatorial anti-RAS therapies. Similar to BRAF-mutant melanomas, combinatorial inhibition of MAPK pathway signaling may be beneficial. Indeed, combined inhibition (by short-hairpin RNA) of BRAF and CRAF achieved synergistic inhibition of growth both in vitro and in vivo in an NRAS-mutant melanoma cell line. 64 In this regard, first-generation pan-RAF inhibitors, such as sorafenib or RAF265, may also be effective as combinatorial agents. 65, 66 Further, RO5126766, a dual MEK/RAF inhibitor, produced a partial response in one of two NRAS and in two of five BRAF melanoma patients. 67 Thus, the MAPK cascade is attractive for intra-pathway combinatorial targets downstream of NRAS, with RAF, MEK and ERK providing for a multiplicity of potentially additive inhibitors.
Targeting PI3K-AKT Canonical pathway schematics often show MEK and PI3K signaling cascades as two of the primary downstream effectors of RAS. 68 The activation of PI3K by NRAS is suggested by the mutual exclusivity of NRAS and PTEN mutations in melanoma, in contrast to the frequent co-occurrence of PTEN loss with BRAF mutations. 5 Correspondingly, dual MEK and PI3K inhibition has been tested in many RAS-mutant cancer models, including melanoma. 69 In vitro, combined treatment of MEK inhibitors (U0126 or PD98059) with the mTOR inhibitor rapamycin led to additive growth inhibition in the NRAS-mutant WM852 cell line. 70 In vivo, the PI3K inhibitor LY294002 in combination with U0126 caused tumor regression in nearly 80% of transgenic mice in which melanomagenesis was driven by a transgenic mutant HRAS and the carcinogen DMBA. 71 A more recent preclinical study using a different transgenic HRAS model also found potent synergy between the MEKi AZD6244 and the dual-PI3K/mTOR inhibitor BEZ235, achieving a 37% (7/20) objective response rate. 72 Whether the results from HRAS models will translate to NRAS melanoma remains to be seen.
Currently, there are very limited data on the efficacy of MAPK plus PI3K combinations in NRAS-mutant melanoma patients, but many trials are ongoing (Table 1) . A critical parameter will be whether sufficient inhibition of each pathway can be achieved at clinically tolerated doses.
Targeting the cell cycle (CDK4) Another approach to tackling RAS signaling is to determine first what a 'perfect' targeted therapy would look like. Recently, an inducible genetically engineered mouse model of NRAS-mutant melanoma (iNRAS) was used to broadly interrogate pathways critical to the pathogenesis of this oncogene (Figure 2) . 55 In the setting of a CDKN2A-null background, doxycycline-inducible and melanocyte-restricted expression of NRAS Q61K efficiently formed spontaneous melanomas. Conversely, withdrawal of doxycycline resulted in complete loss of NRAS Q61K expression by 4 days, and tumors regressed completely by 10 days. Characterization of such 'NRAS-extinguished' tumors provides a positive control for guiding pharmacological combinations. Indeed, treatment with MEK inhibitors (trametinib and selumetinib) failed to achieve tumor regression despite marked inhibition of P-ERK expression, suggesting that these drugs are 'missing' the inhibition of other critical pathways. Pathway analysis of the differences in gene expression incurred by NRAS extinction and MEK inhibition identified marked differences in cell-cycle regulation. Quantitative histological analysis of apoptotic and proliferative markers confirmed that while both NRAS extinction and MEK inhibition induced apoptosis, only NRAS extinction achieved significant inhibition of mitotic activity. Quantitative proteomic profiling similarly identified significantly greater inhibition of retinoblastoma protein phosphorylation with NRAS extinction. Thus, multiple lines of evidence supported that MEK inhibition alone resulted in incomplete blockade of NRAS-induced proliferative signals, suggesting that combined targeting of that pathway could improve anti-tumor efficacy. Transcriptional regulatory associations in pathways, a systems biology analysis, identified CDK4 as the most likely regulator of this differential effect. Treatment of the iNRAS mouse with the CDK4/6 inhibitor PD-0332991 alone failed to induce tumor regression, but significant tumor regression was observed when it was combined with trametinib, including complete tumor responses in one third of the mice. Similar results were observed in a xenograft model using the NRAS-mutant human melanoma cell line SB-2. The discovery of a critical role for cell-cycle inhibition as a combinatorial target was unexpected but fortuitous, as a number of inhibitors against critical mediators are now in various stages of clinical testing. PD-0332991 has demonstrated anti-tumor activity across multiple cancer types, including melanoma, 73, 74 while other CDK4/6 inhibitors (that is, LEE01 and LY-2835219) are in on-going trials (Table 1) . Importantly, combined inhibition of MEK and CDK4 at therapeutically effective doses did not affect body mass in mice, suggesting that a feasible safety profile might be achieved in patients.
Dual induction of both apoptosis and cell-cycle arrest thus forms a powerful synergistic combination and opens the question of how to maximally achieve both. Indeed, while the effect of this combination was robust in the genetically engineered mouse model, it did not fully match the phenotypic potency of genetic NRAS inactivation. Pharmacodynamic considerations likely have some role in this: both inhibitors 'wear off' in between doses and were likely not fully inhibitory in the first place. It is also possible that more upstream targets such as RAL, RAC or PI3K might be superior in this regard, with CDK4 as merely a downstream effector of one or more of these pathways. However, arguments can be made for both approaches: while upstream targets could cover a larger number of relevant pathways, downstream targets like CDK4 likely have fewer off-target or unwanted feedback effects. Only time and clinical trials will confirm which approach is more effective and safe.
Other targeted therapies Laboratory work has suggested that inhibition of the SRC oncogene may be beneficial for melanoma. 75, 76 However, in a clinical trial of the SRC inhibitor dasatinib in combination with dacarbazine, responders were RAS/RAF/KIT-wild type, with poor response in four NRAS-mutant melanoma patients. 77 Combined SRC and MEK inhibition may hold some promise, as in vitro results demonstrate that SRC inhibition may oppose certain migratory effects induced by MEK inhibition. 78 RAL also clearly has an important role downstream of NRAS, 79, 80 and the cooperation of RAL with RAF in transforming melanocytes suggests it as a potential co-target with MEK inhibitors. 79 However, no targeted Ral inhibitors have been developed to date.
Another potential NRAS-specific target is the MET oncogene, which serves as a receptor for HGF. An immunohistochemistry survey of melanomas revealed higher MET phosphorylation in NRAS melanomas, and targeted MET inhibition by PHA665752 inhibited both proliferation and migration only in NRAS-mutant cell lines. 81 The MET inhibitor ARQ197 has also reported promising clinical activity in combination with sorafenib, with 2/6 NRAS patients achieving partial responses and the remaining four achieving stable disease. 82 Finally, recent exome sequencing data efforts uncovered recurrent activating RAC1 P29S mutations, including in NRAS-mutant melanomas. 4, 5 RAC is an important regulator of cell motility and has been implicated as an important downstream effector of RAS. Of note, RAC1 inhibitors (that is, NSC23766) are being tested in preclinical models. 83 The global characterization of somatic mutations in melanoma clinical specimens has also demonstrated the molecular heterogeneity of NRAS-mutant melanomas, underscoring the need for broad functional characterizations of potential therapeutic targets.
DISCUSSION AND FUTURE DIRECTIONS
The clinical management of melanoma is evolving rapidly owing to an improved understanding of the molecular pathogenesis of this disease. The successful development of V600-mutant selective BRAF inhibitors for patients with activating BRAF mutations has been an important advance. One of the major challenges in this field now, however, is to convert the growing understanding of the mechanisms of resistance to these agents into therapeutic strategies with additional clinical benefit. This development will be facilitated by incorporating the lessons learned from the development of the BRAF inhibitors. In addition, similar approaches and strategies will likely be needed in order to successfully target other oncogenic drivers in this disease.
Two factors that were critical to the development of the BRAF inhibitors were (1) the identification of the appropriate patients to be treated with these agents, and (2) the achievement of sufficient pathway inhibition at clinically tolerated doses. The identification of multiple mechanisms of resistance to the selective BRAF inhibitors supports that patient heterogeneity remains a significant issue. Thus, combinatorial strategies in this clinical scenario will likely need to be tailored to the underlying resistance mechanism. Similarly, there is also growing evidence that there is molecular heterogeneity among RAS mutations. In addition to variable sensitivity to different inhibitors among NRAS-mutant melanomas, evidence from other disease types suggests that different RAS mutations may activate different effector pathways. 52 This latter concept has not been investigated sufficiently in melanoma, and may help to refine combinatorial strategies to increase their chance of success.
In addition to patient selection, the selection of therapeutic agents and doses that achieve sufficient pathway inhibition in patients will be critical to successful clinical development. As many patients with metastatic melanoma have superficial metastases that are safely amenable to repeated biopsies, this disease presents a relatively unique opportunity to determine the pharmacodynamic effects of new compounds in the stage IV setting. In addition to patients with stage IV disease, clinical trials in patients with high-risk locally advanced disease present a similar opportunity to potentially achieve both clinical benefit and to advance understanding. While the specificity of the selective BRAF inhibitors has allowed for continuous daily dosing that achieves marked MAPK pathway activation at clinically tolerated doses, the targeting of non-mutated drivers represents a significant pharmacological challenge. Isoform-specific inhibitors against particularly critical effectors may result in sufficient selectivity to allow for adequate target inhibition with acceptable toxicity. Alternatively, a relatively under-explored strategy is the use of intermittent dosing schedules. The functional studies with PI3K-AKT pathway inhibitors suggest that they not only increase the apoptosis achieved by BRAF or MEK inhibitors, but that apoptosis is induced more quickly. Thus, it is possible that intermittent dosing with relatively high doses of these agents may provide the sufficient degree and duration of pathway inhibition to achieve clinical synergy, even if those doses are not tolerable with continuous dosing. The clinical evaluation and development of both isoform-specific inhibitors and alternate dosing strategies, however, will critically depend upon an improved understanding of the biomarkers that correlate with achievement of synergistic anti-tumor activity.
While the use of highly selective agents to achieve an acceptable therapeutic index has a strong clinical rationale, the identification of multiple different resistance mechanisms to BRAF inhibitors suggests that it may be necessary to broadly inhibit multiple pathways/targets concurrently. Indeed, different progressing lesions within the same patient after treatment with selective BRAF inhibitors may exhibit different mechanisms of resistance. 19, 84 As several of the molecular changes that mediate resistance that have been identified to date are epigenetic in nature, epigenetic modifiers such as histone deacetylase inhibitors may achieve clinical success through the inhibition of multiple mechanisms/targets at the same time. 85 Multiple pathways could also be targeted through the use of heat shock protein inhibitors, which destabilize many of the proteins involved in key cellular pathways, including but not limited to the RAS-RAF-MEK-ERK and the PI3K-AKT signaling pathways. 86 Again, biomarkers to guide the evaluation of both the various available agents and possible dosing schedules will be important to the rational development of such strategies.
The developments in the targeting of melanomas with activating BRAF and NRAS mutations are promising. Similarly, some successes have been reported with the use of KIT inhibitors in melanoma patients with activating KIT mutations. 87 However, many patients with KIT mutations do not respond to these inhibitors, and many clinical responses are transient. Interestingly, in contrast to the experience in KIT-mutant gastrointestinal stromal tumors, to date there have been no reports of secondary KIT mutations in the progressing melanomas. The development of targeted therapies for activating GNaQ/11 mutations, which together are present in B80% of uveal melanomas, is also just in its infancy. The recent publication of whole-exome sequencing data, and the imminent release of data from the melanoma TCGA effort, present many more candidate therapeutic targets. While the likelihood is that combinatorial strategies will likely require initial achievement of successful targeted therapies to directly inhibit the oncogenic drivers and/or their related signaling pathways, there is also a strong rationale to combine these approaches with other therapeutic modalities. The parallel development and successes of immunotherapies, with the growing evidence that the anti-tumor immune response is strongly influenced by oncogenic pathways in the tumor cells, reinforces the need to examine both the positive and negative effects of targeted therapies on the immune system. Further, it is also likely that angiogenesis and oncogenic signaling pathways are intertwined in this disease, providing another potential combinatorial approach with existing and evolving strategies to target the tumor's blood supply. Finally, the recent insights into the direct impact cells in the tumor microenvironment have on oncogenic signaling pathways in the tumor cells highlight another key variable to incorporate in the development of clinically effective treatments.
The efficient development of effective therapeutic strategies will require integrated efforts across many disciplines (targeted therapy, immunotherapy, angiogenesis, tumor microenvironment, cellular metabolism, and so on) that have traditionally worked largely in isolation from each other. As our understanding of the inter-relatedness of these processes grows, it is imperative that both preclinical and clinical studies incorporate these different facets to identify and develop rational therapeutic strategies for this highly aggressive disease. While this represents a large challenge, based on the rapid pace of discovery and development in each of these disciplines in recent years, and the existing proofof-concept examples of how these insights can result in clinical benefit, there is true optimism that clinically meaningful improvements in melanoma are attainable in the near future.
CONFLICT OF INTEREST
MAD has served on advisory boards for GlaxoSmithKline, Genentech and Novartis, and has received research funding from GlaxoSmithKline, Genentech, AstraZeneca, Merck and Myriad.
